GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Schrodinger Inc.
Schrödinger is a company whose computational platform is used to accelerate drug discovery. Its stock price is a bet that physics-based simulations can revolutionize pharmaceutical R&D. The chart reflects both customer successes and the company's own programs.
Share prices of companies in the market segment - It med
Schrödinger is a company whose computing platform is used to accelerate drug discovery. Its segments include software sales and proprietary drug development programs. We classify it as part of the IT med sector, and the chart below reflects the dynamics of the entire digital biotechnology industry.
Broad Market Index - GURU.Markets
Schrödinger is a biotech and software company whose computing platform helps accelerate the discovery of new drugs and materials. Its unique role makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Schrödinger compares to it.
Change in the price of a company, segment, and market as a whole per day
SDGR - Daily change in the company's share price Schrodinger Inc.
The daily price change of Schrodinger, whose platform combines physics and AI for drug discovery, reflects the volatility of the biotech sector. Change_co measures sensitivity to news about partnerships and developments. This metric forms the basis for analysis in the computational biology sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - It med
Schrödinger, Inc. is a platform for physics-based drug discovery. This chart highlights the sector's high volatility. Comparing it to SDGR, which combines software and in-house R&D, helps us appreciate its unique business model.
Daily change in the price of a broad market stock, index - GURU.Markets
Schrödinger is a company whose computer modeling platform is used to accelerate drug discovery. Its business operates at the intersection of IT and biotech. The chart below shows overall market volatility, which can be used to assess how the market perceives this business model.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Schrodinger Inc.
Schrödinger is a unique company whose computational platform accelerates drug development. Its year-over-year performance reflects both the growth of its software business and the success of its own pipeline of drugs created using its technology.
Annual dynamics of market capitalization of the market segment - It med
Schrödinger, Inc. is a unique company whose physics-based computing platform is used to accelerate drug discovery. It collaborates with pharmaceutical companies and develops its own drugs. The chart below shows how the market is evaluating its hybrid model, which combines software and biotechnology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Schrodinger, with its pharmaceutical modeling platform, is a hybrid of biotech and IT. Its stock price is a speculative bet that its software will revolutionize drug discovery. The chart isn't tied to economics, but rather reflects investors' faith in one of the most ambitious ideas at the intersection of two industries.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Schrodinger Inc.
Schrodinger, a company whose physics-based computing platform is used to accelerate the discovery of new drugs and materials, has monthly fluctuations on the chart reflecting the growth of its software business and the success of its own drug discovery programs.
Monthly dynamics of market capitalization of the market segment - It med
Schrodinger uses a physics-based computational modeling platform to accelerate the discovery of new drugs and materials. It is a technology company operating at the intersection of chemistry, biology, and AI. The graph below illustrates the dynamics of the biotech sector, where computational approaches are becoming the standard in drug development.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Schrödinger uses its computing platform at the intersection of physics and AI to accelerate drug development. This is a unique business model. A chart of the overall market performance allows us to assess how investors perceive Schrödinger: as a biotech company, whose stock is dependent on development news, or as a SaaS company, more sensitive to general technology trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Schrodinger Inc.
Schrödinger, whose platform combines physics and AI to accelerate drug discovery, reacts weekly to news in both biotech and IT. Progress in its own and partner drug development programs, as well as demand for its software, drives unique and volatile dynamics.
Weekly dynamics of market capitalization of the market segment - It med
Schrödinger, with its unique combination of biotech and software, has a complex correlation with the sector. The chart allows us to compare its performance with the biotech industry to see how its software platform allows it to navigate the clinical trial risks common to other companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Schrodinger uses computational physics to accelerate drug discovery. Its platform is unique. This chart will help you understand whether Schrodinger moves at its own pace, determined by contracts with pharmaceutical companies, or whether its dynamics follow general technological market trends.
Market capitalization of the company, segment and market as a whole
SDGR - Market capitalization of the company Schrodinger Inc.
The Schrödinger chart is a financial model of the future of pharmaceuticals. Its market capitalization is based not on drugs, but on a computing platform that enables molecule modeling and accelerates drug discovery. The chart's dynamics are a bet that artificial intelligence and physics-based modeling will fundamentally change the process of drug discovery.
SDGR - Share of the company's market capitalization Schrodinger Inc. within the market segment - It med
Schrödinger uses a cutting-edge computing platform at the intersection of physics and AI to accelerate drug discovery. Its market share reflects the value of its unique software and the potential of its proprietary developments. The chart below shows how much the market is betting on this technological revolution in pharmaceuticals.
Market capitalization of the market segment - It med
Schrödinger uses cutting-edge software to accelerate drug discovery. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect the hope that technologies like Schrödinger's platform will make R&D more efficient.
Market capitalization of all companies included in a broad market index - GURU.Markets
Schrödinger uses computer modeling to accelerate drug discovery. Its market capitalization chart tells the story of the confluence of biotechnology and supercomputers. It shows how a digital platform transforming pharmaceutical R&D is gaining market share in a market dominated by traditional laboratories.
Book value capitalization of the company, segment and market as a whole
SDGR - Book value capitalization of the company Schrodinger Inc.
Schrödinger uses a computing platform for drug discovery. Its book value is represented by powerful supercomputers and offices. The chart below shows its modest physical foundation. The company's main asset is its software and scientific talent, not its physical assets.
SDGR - Share of the company's book capitalization Schrodinger Inc. within the market segment - It med
Schrödinger uses computational physics to discover drugs. It's a pure software company, its asset is the platform, not the laboratories. Its tangible asset ratio is negligible, which perfectly illustrates its business: revolutionizing pharmaceuticals with code, not hardware.
Market segment balance sheet capitalization - It med
Schrödinger is creating a software platform for drug discovery, replacing real-world experiments with digital modeling. Its main asset is code, not laboratories. The book value chart vividly illustrates the essence of digital business: minimal physical assets with enormous intellectual value.
Book value of all companies included in the broad market index - GURU.Markets
Schrodinger's assets represent a powerful computing arsenal serving the pharmaceutical industry. Unlike traditional laboratories, its balance sheet reflects the value of supercomputers, servers, and a sophisticated software platform. This is the material foundation that enables modeling of molecular behavior and accelerating the discovery of new drugs, reducing years of research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Schrodinger Inc.
Schrödinger uses a computational platform for drug discovery. Its core value lies not in its servers, but in its unique software and scientific expertise. Its market valuation significantly exceeds its book value, as investors are paying for a technology that can accelerate and reduce the cost of drug development for the entire pharmaceutical industry.
Market to book capitalization ratio in a market segment - It med
Schrödinger uses a computational platform to discover new drugs. Its main asset is software, not laboratories. The chart shows how the market values this intangible asset. The huge gap between market and book value compared to the sector reflects investors' faith in the revolutionary nature of their approach to pharmaceuticals.
Market to book capitalization ratio for the market as a whole
Schrödinger uses computational physics to develop drugs. The company is a platform that combines IT and biotechnology. Its value lies almost entirely in its software and scientific discoveries, not in its tangible assets. The chart shows an extremely high valuation of this business compared to its book value, reflecting the market's faith in its platform.
Debts of the company, segment and market as a whole
SDGR - Company debts Schrodinger Inc.
Schrodinger uses debt to maintain its technological leadership at the intersection of pharmaceuticals and IT. This chart shows how the company is funding the development of its computational drug discovery platform and expanding its own research programs. Debt here is an investment in a unique business model that accelerates the development of new drugs.
Market segment debts - It med
Schrodinger uses a computing platform to accelerate drug discovery. In the medical IT sector, debt can finance both software development and high-cost partnerships with pharmaceutical companies. The chart shows how the financial model of this company, located at the intersection of technology and biotech, aligns with the standards of both sectors.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Schrodinger Inc.
Schrödinger uses a computational platform to discover new drugs, merging technology and biotech. This chart shows how much the company relies on debt to finance its complex research. For a research-intensive business with a long development cycle, maintaining a low debt load is crucial to avoid financial difficulties.
Market segment debt to market segment book capitalization - It med
Schrödinger uses a computational physics platform to accelerate the discovery of new drugs and materials. This unique model, at the intersection of IT and biotechnology, requires investments in supercomputers and science. The chart shows the overall debt burden in the sector, providing context for assessing how the company finances its cutting-edge computational research.
Debt to book value of all companies in the market
Schrödinger uses advanced computing for drug discovery, which requires massive investments in technology. This chart shows the overall debt burden in the market. It helps assess how the company's financial strategy for raising capital for its R&D platforms depends on overall macroeconomic trends and investor risk appetite.
P/E of the company, segment and market as a whole
P/E - Schrodinger Inc.
Schrödinger uses a cutting-edge computing platform to accelerate drug discovery. This chart shows how investors view its unique business model, which combines IT and biotechnology. The high score reflects their belief that their software can dramatically reduce the cost and time of drug development.
P/E of the market segment - It med
Schrödinger is a unique company at the intersection of IT and biotechnology. This chart shows the average P/E for the scientific software segment, reflecting a belief in the digitalization of R&D. A company's P/E above this average indicates that investors consider its computational platform for drug discovery a more powerful and promising tool than other companies in this field.
P/E of the market as a whole
Schrödinger uses a computing platform to accelerate the discovery of new drugs and materials. The company operates at the intersection of IT and biotechnology, offering a unique R&D service. This chart illustrates the overall market sentiment. It allows one to understand whether Schrödinger is valued as a technology company or a pharmaceutical company, and whether its value depends on its overall appetite for innovation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Schrodinger Inc.
Schrödinger uses a cutting-edge computing platform to accelerate the discovery of new drugs and materials. The company's valuation, shown on the chart, is based on expectations for its software and the success of its own and partner drug development projects. This forecast represents the platform's ability to generate future royalties and revenues.
%20P%2FE%20Schrodinger%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Schrodinger-Inc.&v=1772631087032 "Chart of the company's future (projected) P/E Schrodinger Inc.")
Future (projected) P/E of the market segment - It med
Schrödinger uses a cutting-edge computing platform to accelerate drug discovery. This chart compares the company's profitability expectations with its industry. It allows one to assess the market's confidence in Schrödinger's unique business model, which combines software sales and drug development, compared to traditional IT or biopharma companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-It-med&v=1772631087039 "Future (projected) P/E graph of the market segment - It med")
Future (projected) P/E of the market as a whole
Schrödinger uses its computing platform at the intersection of physics and artificial intelligence to accelerate the discovery of new drugs. For a company whose revenue depends on long-term R&D contracts with pharmaceutical giants, the overall market backdrop, as seen in the chart, is of paramount importance. Market optimism stimulates investment in research, expanding Schrödinger's client base.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772631087043 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Schrodinger Inc.
Schrödinger uses a computing platform to accelerate the discovery of new drugs and materials. The company's revenue comes from software sales and partnerships with pharmaceutical giants. This chart shows the balance between stable software revenue and potentially large, but irregular, payments from partner programs.
Profit of companies in the market segment - It med
Schrodinger uses a computing platform at the intersection of physics and AI to accelerate drug discovery. This graph, which shows revenue in the medical technology segment, illustrates how innovation is changing the industry. The success of Schrodinger's platform in reducing the time and cost of drug development directly impacts the profitability and growth of the entire pharmaceutical sector.
Overall market profit
While this chart illustrates the cyclicality of corporate profits, the pharmaceutical sector often operates at its own pace of innovation. Schrödinger accelerates drug development with its advanced computing platform. The company's value is less dependent on economic cycles and more dependent on scientific breakthroughs, offering a unique perspective on value creation in biopharma.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Schrodinger Inc.
Schrödinger uses a cutting-edge computing platform to accelerate drug discovery. The revenue projections shown here reflect market expectations for its software and drug development efforts. Growth is dependent on new contracts with pharmaceutical companies and progress in its own research programs.
%20profit%20of%20the%20company%20Schrodinger%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Schrodinger-Inc.&v=1772631087071 "Graph of future (projected) profit of the company Schrodinger Inc.")
Future (predicted) profit of companies in the market segment - It med
Schrödinger uses a cutting-edge computing platform to accelerate the discovery of new drugs and materials. This chart shows revenue forecasts for the medical IT solutions segment. It allows one to assess how the company's unique technology, which combines science and software, compares to overall financial expectations for digitalization in the pharmaceutical and biotech industries.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-It-med&v=1772631087085 "Graph of future (predicted) profits of companies in a market segment - It med")
Future (predicted) profit of the market as a whole
Schrödinger uses a computing platform to accelerate drug discovery. The company operates at the intersection of IT and biotechnology. The overall profit forecast reflected here affects it in two ways: on the one hand, pharmaceutical giants (its clients) may cut R&D budgets during the crisis, while on the other, its technology helps save money on development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772631087104 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Schrodinger Inc.
Schrödinger uses a cutting-edge computing platform to accelerate the discovery of new drugs and materials. This metric, which links market capitalization to revenue, reflects the high valuation of its unique technology platform. Investors pay a premium for every dollar of sales, believing its software will revolutionize R&D in science-intensive industries.
P/S market segment - It med
Schrödinger has revolutionized drug and materials discovery with its physics-based computational platform. It enables the modeling of molecular behavior, accelerating research and reducing costs for pharmaceutical companies. This chart shows how the market values its unique business model, which combines software and scientific development, compared to the industry average.
P/S of the market as a whole
Schrödinger uses its computational platform to accelerate the discovery of new drugs and materials, collaborating with leading biopharmaceutical companies. The company's value lies in its unique technology. This chart shows how the market as a whole values its revenue, providing insight into how Schrödinger's research-intensive platform compares to traditional industries.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Schrodinger Inc.
Schrodinger uses a cutting-edge computing platform to accelerate drug discovery. This chart illustrates how investors value the company based on its projected software revenue and collaborations with pharmaceutical companies. It reflects expectations for the growing adoption of digital technologies in the pharmaceutical industry and the success of its own developments.
%20P%2FS%20Schrodinger%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Schrodinger-Inc.&v=1772631087154 "The graph of the company's future (projected) P/S Schrodinger Inc.")
Future (projected) P/S of the market segment - It med
Schrödinger uses a cutting-edge computing platform to accelerate the discovery of new drugs and materials. The chart shows how the market values the company's future revenue relative to its IT and biotech competitors. Above-average earnings indicate confidence in the uniqueness of its technology, while below-average earnings may indicate a long commercialization cycle and intense competition.
%20P%2FS%20market%20segment%20graph%20-%20It%20med&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-It-med&v=1772631087182 "Future (projected) P/S market segment graph - It med")
Future (projected) P/S of the market as a whole
Schrödinger uses a computing platform to accelerate the discovery of new drugs and materials. The company's revenue comes from software sales and collaborations with pharmaceutical companies. This indicator reflects investors' overall confidence in the growth of the tech and biotech sectors, where innovation drives future revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772631087188 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Schrodinger Inc.
This chart illustrates the commercialization of science in its purest form. Schrodinger generates revenue by providing its physics-based computational platform to accelerate drug and materials development. The sales growth reflects the growing recognition that computer modeling is a key tool for reducing costs and time in pharmaceutical research.
Sales of companies in the market segment - It med
Schrodinger has created a cutting-edge computing platform that dramatically accelerates the discovery of new drugs and materials. The company collaborates with leading pharmaceutical giants. This chart shows the total revenue in the medical and biotechnology IT solutions sector, demonstrating the scale of the market where Schrodinger's software is a game-changer.
Overall market sales
Schrodinger, Inc. offers a computational platform for drug discovery, accelerating research for pharmaceutical companies. Its success is linked to the level of investment in biotech R&D. This graph, reflecting the overall health of the economy, serves as an indicator of capital availability. The more active the economy, the more pharmaceutical giants and startups are willing to invest in innovative platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Schrodinger Inc.
Schrödinger, Inc. provides an advanced physics-based software platform to accelerate drug discovery and materials development. Its revenues come from software licensing and collaborative research programs. This chart illustrates the expected adoption of computational methods in pharmaceuticals and biotechnology to improve R&D efficiency.
%20sales%20of%20the%20company%20Schrodinger%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Schrodinger-Inc.&v=1772631087307 "Schedule of future (projected) sales of the company Schrodinger Inc.")
Future (projected) sales of companies in the market segment - It med
Schrödinger uses its computational platform to discover new drugs and materials. The forecasts presented segment future revenue between software sales and revenue from proprietary and partner drug discovery programs. This shows which portion of the business, according to analysts, will be the company's primary growth driver.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-It-med&v=1772631087315 "Schedule of future (projected) sales of companies in the market segment - It med")
Future (projected) sales of the market as a whole
The future state of the economy, reflected in this chart, is critically important to Schrödinger. The company uses a computing platform to accelerate drug discovery. Its revenue depends on the research budgets of pharmaceutical and biotech companies, which are directly correlated with the overall investment climate and economic growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772631087338 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Schrodinger Inc.
Schrödinger uses its physics-based computing platform to accelerate drug discovery. This chart shows how effectively the company monetizes its unique technology. Profitability comes from two streams: stable software licensing revenue and potentially huge royalties from successful drugs developed in partnership with pharmaceutical companies.
Market segment marginality - It med
Schrödinger uses a cutting-edge computing platform to accelerate the discovery of new drugs and materials. The company monetizes its technology through software sales and participation in drug development. Profitability depends on the success of these two activities. This chart shows profitability in related sectors, helping to assess the effectiveness of Schrödinger's unique hybrid business model.
Market marginality as a whole
Schrödinger uses a computing platform to accelerate drug discovery. The company's success depends on the R&D budgets of pharmaceutical giants. This chart is an indicator of the health of the entire economy. It shows whether large pharmaceutical companies have sufficient profits to invest in cutting-edge and expensive technologies like those offered by Schrödinger.
Employees in the company, segment and market as a whole
Number of employees in the company Schrodinger Inc.
Schrödinger uses a computational platform to accelerate drug discovery. This graph reflects the company's intellectual capital: a team of scientists, programmers, and computational chemists. The growth in the graph indicates expanded collaboration with pharmaceutical companies and the expansion of internal R&D programs, confirming the demand for their unique technologies.
Share of the company's employees Schrodinger Inc. within the market segment - It med
Schrödinger combines physics, chemistry, and AI to create a platform that accelerates drug discovery. The company's value lies in its unique talent pool. This chart shows the proportion of Schrödinger's total scientific and IT talent in computational chemistry and biology. This reflects its intellectual prowess and its role in transforming the pharmaceutical industry.
Number of employees in the market segment - It med
Schrödinger uses advanced computing platforms to accelerate the discovery of new drugs and materials. The chart reflects employment in the medical IT niche. The growing number of specialists in this field underscores the trend toward digitalization in pharmaceuticals and chemistry, confirming the relevance and demand for Schrödinger's unique software platform for scientific research.
Number of employees in the market as a whole
Schrödinger uses cutting-edge software to accelerate the discovery of new drugs. They operate at the intersection of technology and pharmaceuticals. While this graph illustrates general trends, Schrödinger's growth is driven by demand for their computational platform from biopharmaceutical companies. Their staff is comprised of unique specialists, whose hiring is driven by innovation.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Schrodinger Inc. (SDGR)
Schrödinger uses a computing platform to accelerate drug discovery. It's a prime example of a business built on intellectual capital. This chart shows how the market values their software, which enables a small team of scientists and developers to generate colossal value, resulting in a very high cost per employee.
%20of%20the%20company%20Schrodinger%20Inc.%20(SDGR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Schrodinger-Inc.-SDGR&v=1772631087505 "Chart of market capitalization per employee (in thousands of dollars) of the company Schrodinger Inc. (SDGR)")
Market capitalization per employee (in thousands of dollars) in the market segment - It med
Schrodinger uses physical and chemical modeling and machine learning to accelerate drug discovery. They are a unique IT company operating at the intersection of biotech. Their core asset is their computing platform. This metric helps understand how the market values their scalable software platform for use in science-intensive industries.
%20by%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-It-med&v=1772631087509 "Market capitalization per employee (in thousands of dollars) by market segment - It med")
Market capitalization per employee (in thousands of dollars) for the overall market
Schrödinger uses a computing platform to accelerate the discovery of new drugs and materials. It's a unique combination of IT and biotechnology, where value is created by algorithms and scientific expertise. This chart shows how the market values a company where the intellectual work of each employee is multiplied by the power of cutting-edge software.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772631087529 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Schrodinger Inc. (SDGR)
Schrödinger is a unique hybrid. The company sells a cutting-edge computational chemistry platform (SaaS) to other pharmaceutical companies and simultaneously uses the same platform to develop its own drugs. This graph shows the net effect: how much profit the high-margin software business generates per employee, which also funds expensive R&D.
%20Chart%20Schrodinger%20Inc.%20(SDGR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Schrodinger-Inc.-SDGR&v=1772631087599 "Company Profit Per Employee (in thousands of dollars) Chart Schrodinger Inc. (SDGR)")
Profit per employee (in thousands of dollars) in the market segment - It med
Schrödinger is "IT-biotech." They've created a "physical" SaaS platform that *simulates* molecules, accelerating R&D in pharma. This graph shows the benchmark for "Med-IT" (SaaS). In this B2B sector, the benchmark is *very* high. Revenue per employee (physicist, engineer) is generated by a "sticky," high-margin "subscription" to their unique software.
%20in%20the%20market%20segment%20-%20It%20med&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-It-med&v=1772631087607 "Chart of profit per employee (in thousands of dollars) in the market segment - It med")
Profit per employee (in thousands of dollars) for the market as a whole
Schrödinger uses a unique platform that combines physics and artificial intelligence for molecular modeling. This accelerates the discovery of new drugs. Their business is pure software and science. This chart demonstrates how effective their model, based on elite R&D and software, is in generating profit per employee compared to the national average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772631087640 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Schrodinger Inc. (SDGR)
Schrödinger uses a computational platform to accelerate drug discovery. For a company that combines software and biotechnology, this metric reflects the value of its intellectual property. The graph shows how the team of scientists and developers generates revenue from licensing and collaborations with pharmaceutical giants, monetizing their unique developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Schrodinger-Inc.-SDGR&v=1772631087643 "Sales chart per company employee Schrodinger Inc. (SDGR)")
Sales per employee in the market segment - It med
Schrödinger revolutionized drug discovery by replacing wet labs with computer modeling. Their platform allows pharmaceutical companies to discover molecules faster and more affordably. This graph demonstrates the effectiveness of their business model (SaaS + royalties). Their high revenue per employee is a testament to the scalability of their computing platform.
Sales per employee for the market as a whole
Schrödinger (SDGR) is transforming drug discovery using its physics-based computational platform. It's a hybrid: the company licenses its software (SaaS) to pharmaceutical giants while simultaneously running its own R&D programs. This chart demonstrates the incredible power of the SaaS model. The software platform is nearly infinitely scalable, allowing SDGR to generate enormous revenue per engineer.
Short shares by company, segment and market as a whole
Shares shorted by company Schrodinger Inc. (SDGR)
Schrödinger uses a cutting-edge computational physics and machine learning platform to accelerate drug discovery. They collaborate with pharma giants and conduct their own research. This chart reflects a bearish bet. Skeptics may doubt that the computational platform is truly more efficient than traditional R&D or point out that the company's own drugs could fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Schrodinger-Inc.-SDGR&v=1772631087682 "Short Shares Chart for the Company Schrodinger Inc. (SDGR)")
Shares shorted by market segment - It med
Schrodinger (SDGR) provides a physics- and AI-based computational chemistry platform for drug discovery. They help pharmaceutical companies accelerate R&D. This chart shows the overall sentiment in the medical and biotech IT solutions sector. The increase in short positions in this segment may signal a general cooling of investor sentiment toward biotech, reducing budgets for such platforms.
Shares shorted by the overall market
Schrodinger (SDGR) is a SaaS platform that models drug development for biotechs. This Short_All chart shows a risk aversion. This pessimism is drying up funding for biotechs (SDGR's clients). Ultimately, they have no money left for R&D—Schrodinger's core business.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Schrodinger Inc. (SDGR)
Schrödinger uses advanced computational physics and AI to model molecules, accelerating drug discovery. It's a unique blend of SaaS and biotech. This chart measures investor confidence in their platform. It shows when the stock is overbought due to AI hype or oversold due to a long R&D cycle and unprofitability, reflecting sentiment extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Schrodinger-Inc.-SDGR&v=1772631087719 "RSI 14 indicator chart for the company's stock Schrodinger Inc. (SDGR)")
RSI 14 Market Segment - It med
Schrodinger is a company whose physics- and AI-based computing platform dramatically accelerates the discovery of new drugs and materials. They digitally model molecules. This graph measures the overall excitement in the biotech software and AI sector. It helps determine whether the entire segment is overheated by expectations of a revolution in R&D.
RSI 14 for the overall market
Schrodinger (SDGR) uses an AI platform for drug discovery. This chart is an indicator of hype and capital availability. In the euphoria, investors are ready to fund the "future" (AI + biotech). In a panic, they flee unprofitable R&D projects, and the cash spigot for Schrodinger, which is burning through hundreds of millions, could be shut off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SDGR (Schrodinger Inc.)
Schrödinger is a hybrid of IT and biotech. The company provides a computational chemistry platform for drug discovery and is developing its own pipeline of drugs. This chart shows the average share price forecast by analysts. Their targets are based on both software revenue growth and the likelihood of success of internal developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SDGR-Schrodinger-Inc.&v=1772631087740 "A chart showing analyst consensus forecasts for the expected stock price. SDGR (Schrodinger Inc.)")
The difference between the consensus estimate and the actual stock price SDGR (Schrodinger Inc.)
Schrödinger (SDGR) is a hybrid of IT and biotech. Their computational platform models molecules, accelerating drug R&D. This chart shows analysts' assessment of this unique model. It measures the gap between the consensus target and the price, reflecting the potential they see in both their SaaS business and their own drug pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SDGR-Schrodinger-Inc.&v=1772631087756 "A chart showing the difference between the consensus forecast and the actual stock price. SDGR (Schrodinger Inc.)")
Analyst consensus forecast for stock prices by market segment - It med
Schrödinger is a company that provides a software platform for computer modeling of molecules, accelerating the development of new drugs and materials. This chart shows the general expectations of analysts in the medical IT sector. It reflects whether experts believe in the further digitalization of R&D in the pharmaceutical industry.
Analysts' consensus forecast for the overall market share price
Schrödinger is a computer-based laboratory. Their software (physical modeling) allows large pharma and biotech companies to predict drug development, saving billions. This graph, reflecting expert expectations, influences their clients. When the market is pessimistic, R&D budgets (especially in biotech) are cut, which hurts demand for their software.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Schrodinger Inc.
Schrodinger is a scientific IT company. Their physics-based computational platform enables pharmaceutical companies to model molecules and accelerate drug discovery. They operate a hybrid model: they sell software and conduct their own R&D. This chart is a summary indicator. It likely reflects the steady growth of their SaaS revenue and the biotech expectations for their in-house R&D pipeline.
AKIMA Market Segment Index - It med
Schrödinger (SDGR) is a disease simulation company; the company is a leader in computational chemistry, providing pharmaceutical companies with a SaaS platform (and its own R&D) that simulates drugs in silico. This comprehensive index evaluates companies. The graph shows the average value for the segment. This benchmark: how does this unique SaaS (and R&D) model (SDGR) differentiate it from the average competitor?
The AKIM Index for the overall market
Schrodinger is a pioneer in the use of physical modeling and software for drug and material discovery. It's "digital chemistry." This chart, reflecting the market average, is just the background. It helps us assess how this unique technology platform serving the pharmaceutical industry compares to overall economic trends and R&D budgets.
